The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analog class, better ...

In an unconventional alliance, North Carolina State Treasurer Dale Folwell, a Republican, spoke on Capitol Hill at a ...

A manufacturer savings program may help reduce the cost of Wegovy. If you have commercial insurance that covers Wegovy, you could pay as little as $0 for a 28-day supply of the medication (for up ...

This summary presents key updates in the health sector. Highlights include UnitedHealth's tech unit customers adopting ...

Novo Nordisk has announced positive Phase IIa results for monlunabant, a small molecule oral CB1 inverse agonist for obesity.

Eli Lilly's long-term growth prospects are strong with improved supply, new growth opportunities, and competitive positioning ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin ...

Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

More Tennessee companies are covering weight-loss injections in health care benefit plans. This could impact the state's high ...

Dudum said: “People believe that compounding cannibalises the market when the commercial drugs are available ... inspected ...

Increased provider rates also contributed to the rise in insurance premiums impacting the Massachusetts Health Connector, ...